CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Sep 07, 2023 8:45am EDT
CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference Sep 05, 2023 8:45am EDT
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy Aug 14, 2023 8:35am EDT
CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones Aug 14, 2023 7:35am EDT
CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Aug 03, 2023 8:00am EDT
CNS Pharmaceuticals (NASDAQ:CNSP) Announces Acceptance of Abstract for Poster Presentation at the 2023 SNO/ASCO CNS Cancer Conference Jul 27, 2023 9:05am EDT
CNS Pharmaceuticals to Participate in the Virtual Investor Summer Spotlight Series Jul 05, 2023 8:45am EDT
CNS Pharmaceuticals (NASDAQ:CNSP) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest Jun 14, 2023 9:05am EDT
CNS Pharmaceuticals (NASDAQ:CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM) May 25, 2023 9:05am EDT
